Fangda assists Brattea in completing its high-value series-D financing_News_About

Fangda assists Brattea in completing its high-value series-D financing

2024 / 04 / 24

Fangda represented Shanghai Brattea Medical Technology Co., Ltd. (“Brattea”) in its series D investment. The transaction was closed in March 2024. Fangda team on this deal was led by partner Luo Ke, and the team members included Elaine Li and Joshua Tsui. Fangda assisted in the drafting and negotiation of transaction documents and the closing process. Brattea mainly engages in the R&D of medical devices in relation to nerve radiofrequency ablation, including Renal denervation (RDN) for hypertension.

Previous：Fangda represents Mindray in its strategic acquisition of the controlling shareholding right of APT, a listed company on the STAR Market Board

Next：Fangda assisted Voneseals in completing a material asset restructuring transaction through equity acquisition of Shanghai Garnor

2026 / 04 / 21

Fangda Assists TJ Biopharma Enter into Agreement with Biogen for Felzartamab Assets in the Greater China Region

2026 / 04 / 21

Fangda Assists NFC in Successful Acquisition of Peruvian Mining Assets

2026 / 04 / 20

Fangda Assists Kazakhstan’s Sovereign Wealth Fund in Issuing its First Panda Bond in China

2026 / 04 / 14

Fangda Assisted Investcorp in Completing its Sale of Controlling Stake at Jianuo Electronics

2026 / 04 / 10

Fangda Advises Drone Power System Company Sanrui Intelligence on its Successful Listing on the ChiNext Board of the Shenzhen Stock Exchange